Merck
CN
  • Photodynamic therapy in Bowen's disease: influence of histological features and clinical characteristics on its success.

Photodynamic therapy in Bowen's disease: influence of histological features and clinical characteristics on its success.

Dermatology (Basel, Switzerland) (2014-11-18)
Annet Westers-Attema, Bjorn G P M Lohman, Fleur van den Heijkant, Patty J Nelemans, Veronique J Winnepenninckx, Nicole W J Kelleners-Smeets, Klara Mosterd
摘要

In Bowen's disease (BD) there is no consensus on optimal treatment. Photodynamic therapy (PDT) is an effective non-invasive treatment modality for BD with excellent cosmetic results. This retrospective study examines whether clinical and histological features of BD impact PDT response. Patients with previously untreated BD from 2002 until 2007 were identified at the Maastricht University Medical Centre. Patients treated with PDT were included. All histological slides were re-examined. During the study period 98 tumours were treated with PDT. In univariate analysis severe atypia and higher age were associated with decreased probability of clinical clearance. Higher age was also associated with an increased risk of recurrence. In multivariate analysis severe atypia remained the only independent risk factor for therapy failure. In patients with BD, severe atypia and higher age are associated with an increased risk of treatment failure after PDT.

材料
货号
品牌
产品描述

Sigma-Aldrich
5-氟脲嘧啶, ≥99% (HPLC), powder
Sigma-Aldrich
5-氨基乙酰丙酸盐 盐酸盐, ≥98%
Sigma-Aldrich
5-氨基乙酰丙酸盐 盐酸盐, BioReagent, suitable for cell culture, powder, ≥98%
Sigma-Aldrich
5-氨基乙酰丙酸盐 盐酸盐, ≥97.0% (AT)
Supelco
氟尿嘧啶, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
3-(2-吡啶基)-5,6-二苯基-1,2,4-三嗪, ≥99%
Supelco
5-氟脲嘧啶, analytical standard
Sigma-Aldrich
氟脲嘧啶, meets USP testing specifications
USP
氟脲嘧啶, United States Pharmacopeia (USP) Reference Standard
氟尿嘧啶, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
5-氟脲嘧啶, Vetec, reagent grade, ≥99%